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We previously reported that soluble decay-accelerating factor (DAF) and coxsackievirus-adenovirus receptor
(CAR) blocked coxsackievirus B3 (CVB3) myocarditis in mice, but only soluble CAR blocked CVB3-mediated
pancreatitis. Here, we report that the in vitro mechanisms of viral inhibition by these soluble receptors also
differ. Soluble DAF inhibited virus infection through the formation of reversible complexes with CVB3, while
binding of soluble CAR to CVB induced the formation of altered (A) particles with a resultant irreversible loss
of infectivity. A-particle formation was characterized by loss of VP4 from the virions and required incubation
of CVB3-CAR complexes at 37°C. Dimeric soluble DAF (DAF-Fc) was found to be 125-fold-more effective at
inhibiting CVB3 than monomeric DAF, which corresponded to a 100-fold increase in binding affinity as
determined by surface plasmon resonance analysis. Soluble CAR and soluble dimeric CAR (CAR-Fc) bound to
CVB3 with 5,000- and 10,000-fold-higher affinities than the equivalent forms of DAF. While DAF-Fc was
125-fold-more effective at inhibiting virus than monomeric DAF, complement regulation by DAF-Fc was
decreased 4 fold. Therefore, while the virus binding was a cooperative event, complement regulation was
hindered by the molecular orientation of DAF-Fc, indicating that the regions responsible for complement
regulation and virus binding do not completely overlap. Relative contributions of CVB binding affinity, receptor
binding footprint on the virus capsid, and induction of capsid conformation alterations for the ability of
cellular DAF and CAR to act as receptors are discussed.
Coxsackie B viruses (CVB) are enteroviruses belonging to
the family Picornaviridae of single positive-stranded RNA vi-
ruses. All known serotypes of CVB use the coxsackievirus-
adenovirus receptor (CAR) as a primary receptor to infect
permissive cells (3, 4, 25). CAR is a member of the CTX
immunoglobulin superfamily (8) and elucidation of its physio-
logic function is the focus of numerous investigators. Human
CAR has been shown to be a component of homotypic inter-
cellular contacts of nonpolarized cells and tight junctions in
polarized cells (9), and mouse CAR has been identified as a
candidate adhesion molecule in the developing mouse brain
(19, 20). Affinity chromatography has also shown that human
CAR binds to immunoglobulin G (IgG) and IgM, but the
biological significance of this finding is currently unclear (7).
CVB serotypes 1, 3, and 5 have additionally been found to bind
decay-accelerating factor (DAF) as a coreceptor (4, 5, 17, 33).
DAF is a member of the regulators of complement activation
gene cluster and is well established as a potent complement
regulator, as well as a ligand for numerous pathogens and the
leukocyte activation marker CD97 (14, 24, 41).
The relative dependence on DAF and CAR expression for
CVB3 infection can be altered, depending on the cell line in
which the virus is propagated. Where the target cells express
both DAF and CAR, infection of low-passage clinical CVB
isolates can be inhibited to various degrees with antibodies to
either DAF or CAR (3, 25). While incubation of wild-type
CVB strains with human fibroblasts or rhabdomyosarcoma cell
lines (DAF positive, CAR negative) result in a nonlytic per-
sistent carrier type infection (31, 34), some strains adapt after
several passages and acquire the ability to lytically infect these
cell lines (5, 31, 32). These resultant strains are characterized
by high-affinity binding to DAF and the ability to hemaggluti-
nate erythrocytes through DAF binding. However, the capac-
ities of DAF and CAR to act as receptors and impart permis-
siveness to infection are not equivalent. Chinese hamster ovary
(CHO) cells transfected with human CAR are fully permissive,
and CVB infection results in subsequent cytolysis (3, 25, 31),
while CHO cells transfected with human DAF will readily bind
large quantities of CVB (36) but are not fully permissive to
infection, even to the DAF-adapted strains (4, 5, 33, 40).
Recently, we reported that soluble recombinant Fc fusion
forms of DAF and CAR can inhibit CVB-mediated myocardi-
tis in mice (43, 44). However, CAR-Fc was found to addition-
ally inhibit CVB-mediated pancreatitis, while DAF-Fc did not.
To address these differences in CAR and DAF interactions
with CVB in vivo, we have developed in vitro blocking assays
* Corresponding author. Mailing address: Virus Receptor and Im-
mune Evasion Group, School of Medicine, Cardiff University, Henry
Wellcome Building, 3rd floor, Heath Park, Cardiff CF14 4XN, United
Kingdom. Phone: 44 02920 742471. Fax: 44 02920 744001. E-mail:
SpillerB@cardiff.ac.uk.
12016
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
using soluble recombinant receptors. Given that the virus is
likely to complex with multiple DAF and/or CAR molecules on
the cell surface, the effect of valency on infection blocking
efficacy was examined by comparing monomeric and dimeric
forms of soluble DAF and CAR. The ability of soluble recom-
binant forms of CAR and DAF to cause reversible or irrevers-
ible CVB neutralization in vitro was also analyzed. To examine
the biophysical basis of these differences, the binding kinetics
to CVB were also elucidated for monomeric and dimeric forms
of DAF and CAR by surface plasmon resonance (SPR) anal-
ysis.
MATERIALS AND METHODS
Virus strains. Defined CVB serotypes 1, 3, and 5, the kind gift of Brian
Megson, Public Health Laboratory Service, Colindale, London, United King-
dom, were adapted to a rhabdomyosarcoma (RD) cell line through serial prop-
agation. Cardiopathogenic CVB3 strains were generously provided by Charles
Gauntt (University of Texas Health Sciences Center, San Antonio, TX), and
Reinhard Kandolf (University of Tubingen, Tubingen, Germany), and these
viruses were passaged in HeLa cells with regular inoculation and recovery from
A/J mice.
Cell lines. Human RD and HeLa cells were obtained from the European
Collection of Animal Cell Cultures, Porton Down, United Kingdom. The IB-
RS-2 (IBRS) pig kidney cell line was obtained from the American Type Culture
Collection, Manassas, VA. Primary human foreskin fibroblasts (HuFF) were
obtained by standard isolation procedures in-house. All cells were grown in
Dulbecco’s modified essential medium containing glutamine and penicillin-strep-
tomycin and supplemented with 10% fetal calf serum (all purchased from Gib-
coBRL, Paisley, United Kingdom).
Soluble recombinant DAF and CAR. Construction, expression, and purifica-
tion of the CVB receptors DAF and CAR, fused to the carboxy terminus of
human IgG1 Fc (DAF-Fc and CAR-Fc), are described elsewhere (16, 44).
Monomeric DAF was produced using a Pichia pastoris expression system as
previously described (29). Monomeric CAR and DAF were also produced by
proteolytic cleavage of purified Fc fusion proteins with papain-agarose (Sigma).
Briefly, 10 mg of each protein was dialyzed into 20 mM phosphate–2 mM EDTA
buffer (pH 7.4) and incubated with 50 g of agarose-conjugated papain for 1 h
on ice. Complete cleavage and integrity of released DAF and CAR fragments
were investigated by silver-stained sodium dodecyl sulfate-polyacrylamide gel
electrophoresis to ensure the correct molecular mass of resultant fragments. The
papain-agarose was removed by centrifugation (10,000  g for 3 min), and the
supernatant containing the cleaved proteins was run over a ProSep-A column
(Amersham) to remove the released Fc fragments. Column flowthrough and
subsequent phosphate-buffered saline (PBS) washes containing only the released
DAF or CAR were concentrated and buffer exchanged back into PBS by using
an Amicon concentrator with a 10-kDa cutoff filter. Complete removal of Fc
fragments and uncleaved protein was confirmed by Western blot analysis using
the antibodies listed below. Protein concentration was determined by an enzyme-
linked immunosorbent assay using monoclonal anti-DAF or anti-CAR antibod-
ies (see below) to capture antigen and rabbit polyclonal antiserum raised against
monomeric DAF or CAR to detect captured antigen. Plate-bound rabbit anti-
body was developed with horseradish peroxidase-conjugated goat anti-rabbit
immunoglobulin antibody (Bio-Rad Laboratories) and detected with OPD tab-
lets (DAKO) per the manufacturer’s instructions. The concentration of stan-
dards was determined by an in-house acid hydrolysis method, and all stocks were
standardized to 1 mg/ml.
Antibodies. Mouse monoclonal antibody (MAb) recognizing DAF (MBC1)
was a gift of Claire Harris (Cardiff University), and the MAb anti-CAR antibody
(BRAD30) was generated in-house. The hybridoma cell line OX23, secreting
mouse monoclonal anti-human factor H, was obtained from the European Col-
lection of Animal Cell Cultures and was used as the isotype-matched control for
the mouse MAbs. Rabbit polyclonal antisera were raised against soluble recom-
binant human DAF and CAR in-house. Rabbit polyclonal antiserum raised
against soluble HHV-8 open reading frame 4, also raised in-house, provided a
control antibody for the rabbit polyclonal antiserum. Phycoerythrin-conjugated
goat anti-mouse Ig secondary antibody was purchased from DAKO, Ltd. (Angel
Drove, Ely, United Kingdom) and phycoerythrin-conjugated goat anti-rabbit Ig
secondary antibody was purchased from Sigma Chemical Co. (Poole, United
Kingdom). Horseradish peroxidase-conjugated goat anti-rabbit Ig secondary an-
tibody was purchased from Bio-Rad Laboratories, Ltd. (Hemel Hempstead,
United Kingdom).
Virus titration and blocking assays. A total of 10,000 cells of each cell line to
be tested were seeded into each well of 96-well plates 24 h prior to infection. A
10-fold dilution series was made for each virus in ice-cold serum-free cell me-
dium and then mixed with an equal volume of serum-free cell medium (control)
or DAF-Fc or CAR-Fc (to a final concentration of 0.6 M) in ice-cold serum-
free cell medium. After the virus and inhibitor (or control) were allowed to
complex on ice for 30 min, 100 l per well of each test sample was overlaid on
the cells and allowed to incubate for 72 h in a CO2 cell incubator at 37°C. Viable
cells were visualized after staining with 0.1% crystal violet–0.1% formaldehyde in
PBS. Successful blockage of infection was observed as a blue cell layer at 3 days
postinfection. All experiments were repeated several times to assure reproduc-
ibility of results. For experiments where inhibitor concentrations were varied, 104
infectious virus units in ice-cold serum-free medium (final concentration) were
mixed with an equal volume containing (amounts specified in Results) CAR-Fc,
DAF-Fc, monomeric CAR, monomeric DAF, or control medium prior to incu-
bation on ice and treated as detailed above.
Radiolabeling CVB and purification of 160S particles. CVB was labeled with
[35S]methionine by prestarving a 95% confluent 75-cm2 flask of HeLa or RD
cells with serum-free, methionine-free cell medium (Sigma) for 2 h in the CO2
cell incubator. Cells were then incubated with 109 50% tissue culture infective
doses (TCID50) of virus in 1 ml at room temperature with frequent rocking for
30 min, prior to removal of the inoculum and replacement of the methionine-free
cell medium. After 2 h, the cell medium was replaced with serum-free, methi-
onine-free cell medium containing 0.1 MBq [35S]methionine (Amersham), and
incubation continued overnight. Cell supernatant was cleared of cell debris by
centrifugation at 1,000  g for 3 min, and the virus-containing cell supernatant
was filtered through a 0.2-m syringe filter. Radiolabeled virus was pelleted
through a 30% sucrose cushion at 40,000  g overnight and then resuspended
with a 27-gauge needle in PBS containing 0.1% bovine serum albumin (BSA). A
10 to 25% sucrose gradient was made using the BioComp gradient master
(BioComp Instruments, Fredericton, Canada), and the full (160S), procapsid
(135S), and empty (80S) capsids were separated by centrifugation on the gradient
at 40,000  g for 1 h 15 min, followed by fractionation. Virus strains CVB3-CG,
RD, and H were successfully labeled, but attempts to radiolabel and purify
CVB3-RK proved unsuccessful, as this virus was unstable during the purification
process. Ten-microliter aliquots of each fraction were measured by scintillation
counting to identify the radioactive peaks. Peak radioactive fractions correspond-
ing to full capsids (160S) were then pooled, diluted twofold with PBS containing
0.1% BSA, pelleted at 50,000  g for 2 h, and then resuspended in 200 l of
PBS-BSA.
CVB-receptor complex analysis. For neutralization assays, 100,000 cpm of
each virus was incubated with 0.6 M CAR-Fc or DAF-Fc, 108 permissive cells
(RD cells for CVB3-RD; HeLa cells for the rest), or serum-free cell medium on
ice for 1 h. For the permissive cell control, unbound virus was removed by three
washes in ice-cold serum-free cell medium and then resuspended to the original
volume. All samples (unless otherwise specified) were then incubated for 2 h at
37°C on a rotator. Insoluble debris and cells were then removed by centrifugation
at maximum speed in a benchtop microfuge at 4°C for 10 min, then loaded on a
10 to 25% sucrose gradient, and separated as detailed above. Gradients were
separated into 0.5-ml fractions, and 0.1 ml of each fraction was measured by
scintillation counting to determine radioactivity. Each condition was repeated
three times to ensure reproducibility of results. To determine residual infectivity
of peak fractions, 0.1 ml was taken and dialyzed against PBS to remove sucrose
and then used to infect cells to determine the TCID50 as detailed above (without
preincubation on ice or dilution with medium or inhibitors).
Detection of VP4. Viral capsid proteins from the sucrose gradient separations
were precipitated by the addition of 1 ml of 10% trichloroacetic acid to 0.3 ml of
the peak radioactive fractions on ice for 2 h; the precipitated proteins were then
pelleted by centrifugation at 10,000  g in a benchtop microfuge at 4°C. Protein
pellets were washed once with 1 ml of ice-cold acetone and air dried before being
dissolved in Tricine gel sample buffer and separating proteins on a 10% Tricine
gel (Bio-Rad Laboratories). Gels were dried, and radioactive bands were visu-
alized by phosphorimaging (Bio-Rad Laboratories).
Inhibition of classical pathway C3 convertase. Sheep erythrocytes were
washed twice with DGVB (2.5 mM veronal buffer, pH 7.3, 72 mM NaCl, 140
mM glucose, 0.1% gelatin, 1 mM MgCl2, and 0.15 mM CaCl2), suspended at a
concentration of 109 cells/ml, and incubated for 20 min at 37°C with an equal
volume of amboceptor (Boehring Diagnostics, Germany; diluted 1:3,000 in
DGVB) to make EA cells. Purified complement components were purchased
from Advanced Research Technologies (San Diego, Calif.). EAC1 cells were
made by washing the EA cells twice with ice-cold DGVB and resuspending
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them at a concentration of 109 cells/ml; then C1 was added to 1010 cells dropwise
to a final concentration of 5 g/ml and the mixture was incubated with agitation
for 20 min at 30°C. EAC1 cells were washed twice with ice-cold buffer, resus-
pended to the original volume, and incubated with agitation for 20 min at 30°C
with 1 g/ml of C4. The resultant EAC14 cells were incubated in DGVB
containing C2 (5 g/ml) for 5 min at 30°C to allow formation of C3 convertase.
The cells were then placed on ice for 1 min, centrifuged, and resuspended in
prewarmed (30°C) DGVB. An equal volume of these EAC142 cells was
added to a range of dilutions of monomeric DAF or DAF-Fc (in DGVB) and
allowed to incubate at 30°C with constant shaking for 5 min. One-hundred-
microliter aliquots of each sample were removed and added to 100 l of guinea-
pig serum diluted 1:50 in 40 mM EDTA-GVB, and the resultant erythrocyte lysis
was determined following incubation at 37°C for 60 min. The amount of released
hemoglobin was directly proportional to the residual C3 convertase activity
remaining on the EA142 cells and was measured at 405 nm in the supernatant
after the unlysed cells were pelleted by centrifugation at 1,000  g for 4 min.
Purified C4BP was used as a positive control in these experiments, and all
inhibitors were compared to the amount of lysis observed in the absence of
added inhibitors.
SPR. The interaction of DAF and CAR in both monomeric and dimeric forms
with CVB3-RD and CVB3-GC was analyzed by using SPR (Biacore 2000, Bia-
core, Sweden). 160S virus particles were purified from the supernatant of in-
fected cells by polyethylene glycol 8000 precipitation and separation by sucrose
gradient as detailed above. Peak fractions containing 160S particles were pelleted
in a benchtop ultracentrifuge at 40,000  g overnight (8°C) and resuspended in
PBS. Four flow cells of a CM5 sensor chip were activated, each with 20 l of a
mixture of 0.2 M 1-ethyl-3-(3 dimethylaminopropyl) carbodiimide and 0.05 M
N-hydroxy-sulfosuccinimide at a flow rate of 5 l/min, after which purified CVB
strains (in 10 mM Na acetate buffer, pH 4.5) were injected over one flow cell each
to reach 650 resonance units (RU) in the case of CVB3-RD and two different
densities for CVB3-GC (3,400 and 1,500 RU). Nonutilized reactive groups were
blocked with 20 l of 1 M ethanolamine, pH 8.5. A negative control was pre-
pared by activating and subsequently blocking the surface of flow cell 1. The
association kinetics were studied for various concentrations of purified DAF and
CAR dialyzed into 10 mM HEPES-KOH, pH 7.4, supplemented with 150 mM
NaCl, 3.4 mM EDTA, and 0.005% Tween 20. Protein solutions were injected for
140 s during the association phase at a constant flow rate of 30 l/min. The
sample was injected first over the negative control surface and then over immo-
bilized CVB3 strains. Signal (nonspecific binding and changes in refractive index
due to the presence of protein) from the control surface was subtracted. The
dissociation was followed for 500 s at the same flow rate. For analyses of
DAF-CVB interactions, the sensograms returned to baseline within the 500 s;
however, for analyses of CAR binding kinetics, 10 l of 2 M NaCl–100 mM HCl
(pH  2.5) was required to remove bound ligands during a regeneration step.
BiaEvaluation 3.0 software was used to analyze sensograms obtained and to
calculate rate affinity constants.
RESULTS
Inhibition of CVB infection by soluble CVB receptors. We
measured the viral titers of RD-adapted isolates of CVB se-
rotypes 1, 3, and 5 following preincubation with soluble recom-
binant monomeric DAF or dimeric DAF-Fc (Fig. 1A). The
amount of DAF required to inhibit infection of RD cells was
titrated by preincubation of CVB-RD with a fivefold dilution
series from 1.0 M monomeric DAF or 0.5 M DAF-Fc. For
each dilution in these experiments, we used half the molar
FIG. 1. Inhibition of CVB strains by preincubation with soluble receptors. Representative assay showing inhibition of viral infection (the
surviving cell layer is visible as gray) for IBRS cells (B) or RD cells (A) following preincubation of cardiopathogenic CVB3 strains CG or RK with
monomeric soluble CAR or RD-adapted CVB serotypes 1, 3, and 5 with monomeric DAF or DAF-Fc, respectively. The top row represents virus
infection of cells in the absence of inhibitor, while a fivefold dilution of monomeric DAF (1.0 M to 16 nM) or dimeric DAF-Fc (0.5 M to 8 nM)
(A) or monomeric CAR (1.2 M to 19 nM) (B), the former two proteins kept at a molar equivalence for each row. For a complete summary of
all viruses, cell types, and Fc-fusion proteins, see Table 1. Final concentrations of soluble receptors are shown at the edge of the plate for all
receptors.
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concentration of dimeric DAF (DAF-Fc) to keep the valency
of CVB binding sites equivalent to that of monomeric DAF.
Monomeric DAF blocked infection only at the highest concen-
tration tested, whereas DAF-Fc inhibited at higher dilutions
and was found to be 125-fold-more effective at blocking all
serotypes of CVB-RD (Fig. 1A). Since the monomeric DAF
and DAF-Fc were produced by different biosynthetic methods
(yeast expression versus expression in CHO cells) for these
studies, we examined whether the method of recombinant pro-
tein production had any influence on the ability of these pro-
teins to inhibit virus infection. We found that monomeric DAF
released from DAF-Fc by papain cleavage and purified from
contaminants was equivalent in its ability to inhibit CVB in-
fection compared to monomeric DAF produced from Pichia
pastoris (data not shown).
We next investigated the ability of DAF-Fc to inhibit the
cardiopathogenic CVB3 strains CG and RK (Table 1). Neither
of these strains caused cytopathic effects in RD cells or primary
human fibroblasts (HuFF) due to the absence of cell surface
CAR expression (Table 2); however, both CVB3-CG and
CVB3-RK readily infected HeLa cells (Table 1) which ex-
pressed high levels of both DAF and CAR (Table 2). DAF-Fc
caused no block of infection of HeLa cells for either cardio-
pathogenic strain and also failed to inhibit the limited HeLa
cell infection by CVB-RD (Table 1). The pig kidney cell line
(IBRS) was permissive for all of the CVB3 strains tested, and
we have previously shown that infection is via the pig homo-
logue of CAR (37). Preincubation of virus with DAF-Fc inhib-
ited IBRS cell infection by all CVB3 strains by 10 to 10,000 fold
(Table 1). These data suggest that the inhibition of CVB in-
fection by DAF-Fc occurred via steric hindrance of the CAR
binding site of the capsid as it blocked infection of CAR-
positive, DAF-negative (IBRS) cells.
The ability of soluble recombinant CAR to block infection
of cells was also assessed by preincubation of virus with CAR
prior to addition to cells (Table 1; Fig. 1B). Monomeric CAR
was generated from CAR-Fc by papain cleavage and purified
from uncleaved CAR-Fc and the Fc fragments using protein A.
Unlike our findings for soluble DAF, monomeric CAR and
dimeric CAR-Fc were equally capable of blocking CVB3-CG
and CVB3-RK strain infection (data not shown). CAR-Fc
blocked CVB3-RD infection of IBRS cells but not infection of
HeLa cells, RD cells, or fibroblasts (Table 1). Therefore,
CAR-Fc was only able to inhibit CVB3-RD infection of cells
that did not express DAF (Tables 1 and 2).
Inhibition of complement by soluble DAF. The ability of
soluble monomeric DAF and DAF-Fc to regulate complement
activation was also assessed. DAF regulates complement acti-
vation by accelerating the decay of C3 convertases. Conver-
tase-bearing cells were assembled by sequential addition of
purified complement components to antibody sensitized target
sheep erythrocytes. We found that fourfold-more DAF-Fc
(based on protein molarity) was required to provide the same
protection of sheep erythrocytes from complement-mediated
lysis compared to monomeric DAF (Fig. 2). On a molar ratio,
DAF-Fc contains twice the number of functional sites as mo-
nomeric DAF; this means that an 8-to-1 ratio of functional
sites between DAF-Fc and monomeric DAF was required to
achieve equivalent complement regulation. This suggests that
while the dimeric form enhances binding to CVB, this confor-
FIG. 2. Comparison of classical C3 convertase decay acceleration
by monomeric DAF (squares) or dimeric DAF-Fc (circles). All assays
were performed in triplicate, and analyses were repeated at least twice.
Error bars represent standard deviations, and 100% lysis refers to the
lysis without addition of inhibitor.
TABLE 1. Infection of cell lines by CVB3 stains and inhibition with soluble receptorsa
Cell line
inhibitor
Result for:
RD HuFF HeLa IBRS
None DAF-Fc CAR-Fc None DAF-Fc CAR-Fc None DAF-Fc CAR-Fc None DAF-Fc CAR-Fc
CVB3-CG NL — — NL — — 107 107 100 104 102 NL
CVB3-RK NL — — NL — — 105 105 101 105 102 NL
CVB3-RD 105 103 106 107 103 107 103 103 103 103 102 NL
CVB3-H 102 101 103 103 101 103 106 105 103 105 101 NL
a Representative results for several repeated assays are shown. The amount of infectious virus as identified by lysis of the cell layer is shown. The relative changes
of infectivity in the presence of CAR-Fc or DAF-Fc compared to controls were identical between all replications of this experiment. NL, no lysis; —, blocking studies
not performed due to inability to lytically infect these cells.
TABLE 2. Flow cytometric assessment of CAR and DAF
expression on cell linesa
Expression
Cell line
HeLa RD HuFF IBRS
Isotype control 18.0  1.0 13.8  17.0 23.6  7.1 4.2  0.3
Anti-human CAR 531  81.0 13.9  1.2 21.0  2.6 194.4  3.0
Anti-human DAF 5,818  595 247.6  17.0 330.7  9.5 4.3  0.5
a Values indicate mean cell fluorescence (with standard deviations) for deter-
minations made in triplicate, conducted on three separate days.
VOL. 79, 2005 CVB NEUTRALIZATION BY SOLUBLE RECEPTORS 12019
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
mation interferes with the ability of DAF to regulate comple-
ment. We have previously shown that CAR does not regulate
complement (35).
Readaptation of the CVB3-RD strain to HeLa cells.
CVB3-RD did not grow well in HeLa cells (Table 1). However,
by inoculating HeLa cells at a multiplicity of infection of 0.1,
followed by two serial passages, we selected a variant popula-
tion with an enhanced capacity to replicate in this cell type.
This strain, designated CVB3-H, grew to a higher titer in HeLa
cells and had a decreased ability to grow in RD and HuFF cells
by 103 to 104 fold (Table 1). It is interesting that CVB3-H
infection of HeLa and IBRS cells was blocked by CAR-Fc, but
the residual ability to infect RD cells and HuFF was not (Table
1). CVB3-H also retained the ability to be inhibited by DAF-
Fc, as was the parent strain, in HuFF, RD, and IBRS cells.
Therefore, CVB3-H was also included in our further studies as
it combined the cell tropism and inhibition characteristics of
the other three virus strains.
Sucrose gradient separation of CVB3 following incubation
with soluble receptors. Radiolabeled 160S CVB3-CG, CVB3-
RD, and CVB3-H particles (Fig. 3A) were incubated with
either DAF-Fc, CAR-Fc, permissive cells, or cell medium on
ice for 1 h, followed by rotation at 37°C for 2 h, and then
analyzed for conversion from mature infectious particles
(160S) to A particles (135S) or empty capsids (80S) (Fig. 3).
CVB3 strains bound to permissive cells and then eluted from
the cell surface by incubation at 37°C for 2 h (cells were
removed by centrifugation prior to being loaded onto the gra-
dient) served as the positive control for production of A par-
ticles (see below and Fig. 3B). Incubation of CVB3-CG and
CVB3-H strains, but not the CVB3-RD strain, with CAR-Fc
resulted in a decreased sedimentation rate in the gradient,
consistent with the formation of A particles (Fig. 3C). De-
creased sedimentation was also observed for CVB3-CG, fol-
lowing incubation with CAR-Fc on ice or at room temperature
for 2 h (data not shown). No alteration was observed when
CVB3-CG was incubated with DAF-Fc (Fig. 3D); however,
decreased sedimentation was observed when both CVB-RD
and CVB-H were incubated with DAF-Fc (Fig. 3D).
Determination of A particles formation by loss of VP4. The
formation of A particles is irreversible, partly due to the ex-
ternalization and loss of VP4, an internal capsid protein (11).
We therefore compared the input and eluted radiolabeled
virus particles for the presence of VP4 to confirm that the 135S
particles we observed were A particles (Fig. 4). VP4 was absent
from all radioactive peaks eluted from permissive cells, which
was included as the control for A-particle formation (Fig. 3B
and 4). Despite the evidence of altered sedimentation de-
scribed above for CVB-RD and CVB-H after incubation with
DAF-Fc (Fig. 3D), VP4 was retained in the peak radioactive
FIG. 3. Separation of full capsids (160S), A particles (135S), and empty capsids (80S) by centrifugation through a 10 to 25% sucrose gradient.
Radiolabeled viruses were bound to permissive cells, 0.6 M DAF-Fc, or CAR-Fc or added to cell medium (control) and rotated for 2 h at 37°C,
before cells or particulate debris was removed by centrifugation and loaded onto a sucrose gradient. Fractions (0.5 ml) as taken from the bottom
of the gradient to the top are shown for CVB3-CG (squares), CVB3-RD (triangles), or CVB3-H (circles) and plotted as the percent radioactivity
of the total loaded on the gradient. (A) Virus incubated with cell medium only; (B) virus eluted from permissive cells; (C) virus incubated with
CAR-Fc; (D) virus incubated with DAF-Fc.
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fractions, indicating that the altered mobility was caused by
stable formation of virus complexes with soluble receptor,
rather than the formation of A particles (Fig. 4). In contrast,
no VP4 was present for CVB3-CG or CVB-H following incu-
bation with CAR-Fc, confirming the formation of A particles
(Fig. 4). It is important to note, however, that even though
sedimentation was decreased for CVB3-CG incubated with
CAR-Fc on ice and at room temperature, VP4 was retained for
both of these conditions (data not shown), indicating that the
formation of A particles requires a shift to physiological tem-
perature and that CVB-CAR-Fc can form complexes that im-
pede sedimentation in the gradient.
Recovery of infectious virus from peak radioactive sucrose
gradient fractions. One-fifth of each of the peak radioactive
fractions shown in Fig. 3 was dialyzed against PBS to remove
the sucrose and then used to infect permissive cells. The virus
titer, shown as TCID50 per milliliter, is indicated below each
fraction in Fig. 4. A particles eluted from the cell surface
showed a 104- to 105-fold decrease in infectivity (based on
similar amounts of radioactivity present) when compared to
virus that was mixed with cell medium alone, similar to that
observed for poliovirus neutralization by soluble poliovirus
receptor (12, 21). In all cases where viruses showed a loss of
VP4, they also had a decreased infectivity consistent with A-
particle formation. However, in the case where CVB-RD and
CVB-H had been incubated with DAF-Fc, which showed an
altered sedimentation but no loss of VP4 (Fig. 3D), the recov-
ered virus was as infectious as the virus control, indicating that
an uncoating event had not occurred (Fig. 4).
Measurement of binding affinities of soluble CAR and DAF
for CVB3. To assess whether differences in the affinities of
soluble CAR and DAF for CVB were responsible for the
observed effects on viral infection and stability, we measured
binding affinities of the soluble receptors to immobilized CVB
by SPR, using methods previously employed for echovirus 11
(EV11) (23). We attempted to immobilize both CVB3-CG and
CVB3-RD to a CM5 chip but were unable to immobilize suf-
ficient CVB3-RD to allow confident determination of binding
coefficients. Monomeric and dimeric forms of DAF and CAR
were dialyzed into standard Biacore analysis buffer (see Ma-
terials and Methods), which was of physiological ionic strength,
and binding at a range of soluble receptor concentrations was
analyzed (Table 3). Sensograms collected for various concen-
FIG. 4. Autoradiography of CVB3 capsid proteins from peak radioactive fractions, following sucrose gradient separation. Peak fractions
following incubation with cell medium only (control) or elution from permissive cells, DAF-Fc, or CAR-Fc were precipitated with trichloroacetic
acid and analyzed by Tricine gel electrophoresis. One-hundred-microliter aliquots of these fractions were also dialyzed and assayed for infectivity
on permissive cells, and these values (TCID50) are listed below the relevant fractions.
TABLE 3. Surface plasmon resonance analysis of soluble receptor
affinity for CVB-CGa
Analyte KD (M) ka (M) kd (M)
Monomeric CAR 2.45  107 3.35  103 8.21  104
Dimeric CAR 3.84  1010 1.62  103 6.18  107
Monomeric DAF 3.82  104 NA NA
Dimeric DAF 1.6  106 NA NA
a kd, dissociation rate affinity constant; ka, association rate affinity constant;
NA, not available due to steepness of binding and dissociation curves.
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trations of dimeric and monomeric CAR were evaluated by
using a 1:1 Langmuir model of binding (Biaevaluation 3.0).
Monomeric DAF bound to the CG strain of CVB with the
lowest affinity at an equilibrium dissociation constant (KD) of
3.82  104 M, while dimeric DAF-Fc bound with an affinity
238-fold higher (1.6  106 M) (Table 3). The binding of
monomeric CAR was 6.5-fold better (KD  2.45  10
7 M)
than the binding of dimeric DAF-Fc, and the dimeric form of
CAR, CAR-Fc, resulted in a further 638-fold increase (KD 
3.84  1010 M) over soluble receptor binding for CVB-CG
(Table 3). The lower affinities of DAF than CAR for virus were
coupled with on and off rates that were so rapid that it was
necessary to calculate the binding affinities by using a steady-
state affinity model. When comparing rate affinity constants for
monomeric and dimeric CAR, it was apparent that association
was not affected by dimerization but that the dimeric protein
was dissociating much more slowly than the monomeric CAR.
For this reason, a high-salt, low-pH buffer was required to
release the bound soluble receptors (see Materials and Meth-
ods), while DAF and DAF-Fc completely dissociated under
normal flow conditions. Analysis of DAF-Fc binding to
CVB-CG performed before and after CAR-Fc binding analysis
gave equivalent results, confirming that the regeneration step
required for monomeric CAR and CAR-Fc did not alter the
binding characteristics of immobilized CVB3-CG (data not
shown).
We did attempt to determine if binding of one protein in-
terfered with the binding of the other. Due to the almost
immediate dissociation of monomeric DAF and DAF-Fc, it
was impossible to preload the immobilized CVB virions and
subsequently measure CAR binding. Immobilized CVB (2,000
RU) was preloaded with 0.2 mg/ml CAR-Fc (addition of a
further 200 RU), and no subsequent binding of monomeric
DAF or DAF-Fc was detectable, although monomeric DAF
did bind once the CAR-Fc was removed via a regeneration
step. This indicates that binding of the Fc-fusion forms of these
proteins can interfere with binding of the other protein; how-
ever, we were unable to determine if monomeric forms of both
proteins can concurrently bind to the virus.
DISCUSSION
We have previously investigated the ability of DAF-Fc and
CAR-Fc to inhibit CVB3-mediated disease in mice (43, 44).
We administered either DAF-Fc (43) or CAR-Fc (44) by an
intravenous route while infecting the mice with the cardio-
pathogenic CVB3-CG strain by the intraperitoneal route.
While we found that both CAR-Fc and DAF-Fc could abro-
gate CVB-mediated myocarditis, only CAR-Fc blocked the
development of CVB-mediated pancreatitis, suggesting that it
had additional effects on the virus. Here, we investigated the
basis for these differences, using the same strain of CVB3 and
soluble decoy receptors. The in vivo experiments utilized Fc
fusion forms of DAF and CAR, primarily to enhance the
half-life of the proteins in circulation (30) and to aid purifica-
tion; however, we expanded our in vitro analysis to compare
monomeric and Fc-fusion forms of DAF and CAR. During our
investigations, we also noted that infection of CVB3-CG was
only weakly susceptible to inhibition by DAF-Fc; therefore, we
also included RD-adapted strains of CVB to more fully inves-
tigate the potential of DAF-CVB interactions.
We found that DAF-Fc was much better at inhibiting infec-
tion by RD-adapted strains of CVB1, 3, and 5 than monomeric
DAF (Fig. 1). DAF-Fc also inhibited infection by cardiopatho-
genic CVB strains CG and RK of cells that lacked endogenous
human DAF expression (IBRS cells) (Table 1), an effect that
was lost when these cells were transfected with human DAF
cDNA (data not shown). These data suggested that inhibition
of infection by DAF-Fc was a reversible stearic event; this was
confirmed by the demonstration that DAF-Fc failed to induce
A-particle formation and virus neutralization (Fig. 4). The
observed effective inhibition of CBV-CG infection of mice by
DAF-Fc fits this scenario, since we have previously shown that
the mouse homologue of DAF is unable to bind CVB (36).
The enhanced CVB inhibition of DAF-Fc compared to mo-
nomeric DAF correlated with enhanced viral binding affinity,
as determined by SPR analysis (Table 3). In contrast, mono-
meric CAR and CAR-Fc showed similar inhibition of cardio-
pathogenic CVB strain infection, regardless of CAR expres-
sion by the cell lines (Tables 1 and 2). This may be explained
in part by differences in affinity. Both monomeric and dimeric
CAR bound virus with an affinity higher than that of DAF-Fc,
the latter 104-fold higher (Table 3). Our measured affinity for
monomeric CAR binding to CVB3 (2.45  107 M) was lower
than the affinity for monomeric CAR and fiber knobs from
adenovirus serotypes 5, 12, and 41L (1.5  109 to 7.9  109
M) reported by Kirby et al. (22) but higher than their binding
affinity of CAR for adenovirus serotype 9 (6.4  106 M). The
binding affinity between CAR and CVB that we measured is
similar to values previously found for Ig superfamily virus
receptors that bind and induce A-particle formation of other
picornaviruses; namely, poliovirus and its receptor (1.1 to 2.3
 107 M), as well as human rhinovirus types 3 or 16 and
intercellular adhesion molecule 1 (2.1 107 to 3.1 107 M)
(26, 42). However, whether the nature of protein binding
within the picornavirus capsid canyon structures promotes
high-affinity binding or whether high-affinity binding is a req-
uisite for induction of altered capsid conformation has not yet
been determined. We were unable to immobilize CVB-RD in
sufficient quantities for SPR analysis; however, infection stud-
ies showed that CAR-Fc inhibited CVB3-RD infection of
DAF-negative IBRS cells but not CAR-negative RD cells. It is
important to note, however, that adaptation of CVB strains to
lytic growth in RD cells is an artifact of laboratory virus prop-
agation accompanied by increased ability to bind DAF (refer-
ence 31 and our unpublished observations). Although Shafren
et al. (34) reported that lytic infection of RD cells required the
presence of low levels of CAR on these cells, our flow cytom-
etry analysis found negligible CAR expression with both RD
cells and human fibroblasts (Table 2). Moreover, infection of
RD cells by our CVB-RD strain could not be inhibited by
incubation with CAR-Fc. This implies that our CVB-RD strain
may be capable of truly CAR-independent infection, analo-
gous to the intercellular adhesion molecule 1-independent,
DAF-dependent infection of RD cells, as recently demon-
strated by Newcombe et al. (28).
Expression of DAF alone is not sufficient to mediate lytic
infection, as CVB-RD cells will not lytically infect CHO cells
expressing human DAF (5, 31), while nonadapted CVB strains
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will lytically infect CHO cells expressing CAR (25, 31). These
data suggest that RD-adapted CVB strains may have adapted
to utilize a novel as-yet-unidentified receptor present on RD
cells and human fibroblasts in addition to DAF. If so, it is likely
that the virus has only low affinity for this additional receptor,
as the low-affinity interaction with exogenous soluble DAF is
sufficient to block the interaction and prevent infection. It is
also interesting that CVB3-RD has been reported to be non-
pathogenic in mice (32).
Although dimerization of DAF caused a 100-fold increase in
binding affinity for CVB, this was not the case for its ability to
inhibit complement. DAF-Fc was fourfold-less effective on a
molar basis in inhibiting complement than the monomeric pro-
tein. This is in agreement with a previous report examining
steric hindrance of complement regulation in DAF-Fc proteins
(15). The data suggest that the regions of DAF that regulate
complement and those that bind CVB may overlap but also
have unique regions as well, similar to that previously shown
for echoviruses (41). These conclusions are also supported by
differences in binding of anti-DAF monoclonal antibodies or
molecularly altered forms of DAF that block complement reg-
ulation but not CVB binding, and vice versa (5, 10, 33).
A particles are considered to be an important intermediate
in the uncoating events that result in the delivery of the RNA
genome to the cell cytoplasm (1, 2), and incubation of polio-
virus with soluble poliovirus receptor induces A-particle for-
mation (13, 21, 40). CAR-Fc, unlike DAF-Fc, induced A-par-
ticle formation for CVB (Fig. 4). The formation of A particles
has been noted for CVB3 eluted from permissive HeLa cells:
these particles had a buoyant density of 135S compared to
160S and were missing the smallest capsid protein, VP4 (11).
CAR-Fc induction of A-particle formation induced an irre-
versible loss in infectivity when incubated at 37°C. Although
DAF-Fc formed stable complexes with CVB-RD and CVB-H
strains capable of remaining intact through a sucrose gradient
(Fig. 3D), no A-particle formation was observed (Fig. 4). The
ability to induce an irreversible conformation change in the
capsid likely contributes to the capacity of CAR-Fc to decrease
pathology in CVB-infected mice (44).
In addition to affinity differences, it is likely that the forma-
tion of A particles by CAR-Fc but not DAF-Fc involves dif-
ferences in the capsid binding site for these proteins. The
CAR-specific formation of A particles supports the hypothesis
that canyon binding receptors are required for uncoating. The
canyon is formed primarily by VP1 with a contribution of the
hypervariable “puff” region of VP2, and He et al. have local-
ized the CAR binding footprint to this area (17). While no
direct structural analysis of CVB-DAF complexes has been
performed to date, extrapolations can be made from the cryo-
electron microscope reconstruction of echovirus (EV) 7-DAF
complexes (18) or EV12-DAF complexes (6), which revealed
DAF binding along the twofold axis of symmetry on the EV
capsid. Modeling of capsid mutations in echovirus 11 strains
that had lost DAF binding suggested that DAF bound at the
platform surrounding the fivefold axis of symmetry (38). Both
of these putative binding sites are distant from the canyon and
may explain the inability of DAF to induce A-particle forma-
tion.
A recent report investigated the cellular localization of
CAR, DAF, and CVB, following infection of a pancreatic cell
line with CVB serotype 4 (39). Following CVB4 binding, virus
did not enter via the clathrin-coated pit entry route, where
CAR was predominantly found in the absence of viral infec-
tion, but colocalized with both DAF and CAR and moved en
bloc to the cis-Golgi. These results indicate that although DAF
and CAR may be associated with distinct physiological path-
ways within the cell, they traffic synchronously once associated
with CVB. These findings imply that DAF does not simply act
to sequester the virions for interactions with additional inter-
nalizing receptors but may be an important part of targeting
the virus to the site of replication during entry, hence explain-
ing the wide range of picornaviruses that interact with this
receptor and perhaps making sense of the differing affinities
that the two receptors have for the virus.
Concurrent with the submission of the manuscript, Milstone
et al. (27) published findings similar to those reported here.
They similarly investigated the mechanism behind the inability
of DAF expression to mediate permissive infection of trans-
fected CHO cells, which are in contrast to CHO cells express-
ing CAR. They also examined the ability of soluble and cell-
associated CAR to induce CVB A-particle formation. We have
expanded on their studies by investigating further strains of
CVB3 and provide more extensive investigation of binding
affinities of DAF and CAR binding through SPR analysis.
Although our findings for RD-adapted CVB3 differ somewhat
from theirs, a single passage of our CVB-RD in HeLa cells
generated a phenotype equivalent to their CVB-RD. Sequence
comparison of the CVB-RD strains from both laboratories
may provide additional insight into the CAR binding site for
this virus.
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